Ireland-based biopharmaceutical firm Alkermes has started a Phase III clinical trial of ALKS 8700 for the treatment of relapsing forms of multiple sclerosis (MS).

ALKS 8700 is an oral monomethyl fumarate (MMF) prodrug candidate designed to rapidly and efficiently convert to MMF in the body.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The multicentre, double-blind, active-controlled, five-week Phase III trial will evaluate the gastrointestinal (GI) tolerability of ALKS 8700 compared to TECFIDERA in around 420 patients with relapsing-remitting MS (RRMS).

Alkermes chief executive officer Richard Pops said: “This elective study for ALKS 8700 demonstrates Alkermes’ unique approach to fully characterise the potential value of new medicines, reflecting our commitment to integrating inputs from patients, physicians and payers into our development programmes in response to an increasingly complex healthcare system.

"The data from this study will help determine ALKS 8700’s potential advantages for patients and its future positioning in the fumarate market, which represents a $3bn opportunity in the US."

“The data from this study will help determine ALKS 8700’s potential advantages for patients and its future positioning in the fumarate market, which represents a $3bn opportunity in the US.”

The elective trial is part of the ongoing ALKS 8700 clinical development programme EVOLVE-MS.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the trial, GI symptoms such as nausea, vomiting, upper and lower abdominal pain and diarrhea will be measured using the individual gastrointestinal symptom and impact scale (IGISIS) and the global gastrointestinal symptom and impact scale (GGISIS).

The intensity, frequency, duration and effect of the symptoms on the daily activities will be examined.

Alkermes intends to submit a new drug application (NDA) for ALKS 8700 for the treatment of RRMS to the US Food and Drug Administration (FDA) next year.